Alstom S.A.: Half-year liquidity contract statement for Alstom
7 July 2025 – Under the liquidity contract entrusted by Alstom to Rothschild Martin Maurel, as of June 30, 2025, the following resources appeared in the liquidity account:
0 security
€17 987 200
Over the period from 2025/01/01 to 2025/06/30, the number of transactions processed is as follows:
Number of transactions carried out
Number of securities traded
Amount of transactions (in €)
Buy
19 563
7 262 678
149 362 897.45
Sell
22 488
7 262 678
149 345 792.22
As of 31st of December 2024, the following resources appeared in the liquidity account:
0 security
€ 18 004 305
The implementation of this report is carried out in accordance with AMF decision n°2021-01 of June 22, 2021 renewing the introduction of liquidity contracts on equity securities as an accepted market practice.
The complete transaction template is available in the attached PDF document.
ALSTOM™ is a protected trademark of the Alstom Group.
About Alstom
Alstom commits to contribute to a low carbon future by developing and promoting innovative and sustainable transportation solutions that people enjoy riding. From high-speed trains, metros, monorails, trams, to turnkey systems, services, infrastructure, signalling and digital mobility, Alstom offers its diverse customers the broadest portfolio in the industry. With its presence in 63 countries and a talent base of over 86,000 people from 184 nationalities, the company focuses its design, innovation, and project management skills to where mobility solutions are needed most. Listed in France, Alstom generated sales of €18.5 billion for the fiscal year ending on 31 March 2025. For more information, please visit www.alstom.com.
Contacts
PressPhilippe MOLITOR - Tel. : +33 (0) 7 76 00 97 79 philippe.molitor@alstomgroup.com Thomas ANTOINE - Tel. : +33 (0) 6 11 47 28 60thomas.antoine@alstomgroup.com Investor RelationsCyril GUERIN - Tel.: +33 (0)6 07 89 36 16cyril.guerin@alstomgroup.com Guillaume GAUVILLE - Tel: +44 (0)7 588 022 744guillaume.gauville@alstomgroup.com Estelle MATURELL ANDINO - Tel: +33 (0)6 71 37 47 56 estelle.maturell@alstomgroup.com Jalal DAHMANE - Tel: +33 (0)6 98 19 96 62jalal.dahmane@alstomgroup.com
Attachment
20250707_PR_Contract_Liquidity_S_12025_EN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning with regulatory status in the US and other major markets Medicinal product classification supports unified global regulatory classification, facilitating future global strategies and filings New composition of matter patent for JNJ-1900 (NBTXR3) filed by Nanobitotix PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company. Health authorities in major European countries have agreed to formally reclassify JNJ-1900 (NBTXR3) from a medical device to a drug, completing a process initiated by Johnson & Johnson to harmonize the product candidate's regulatory status with classifications already in place in the United States and other major markets. The reclassification follows updated insights into the product candidate's mechanism of action. In parallel, Nanobiotix has filed a new composition of matter patent for JNJ-1900 (NBTXR3) that aims to reinforce the intellectual property foundation supporting the product candidate. 'These updates reflect our continued commitment to the JNJ-1900 (NBTXR3) program,' said Laurent Levy, co-founder and chairman of the executive board at Nanobiotix. 'We are pleased with the progress achieved with health authorities and proud to continue advancing this potential first-in-class product candidate toward patients in need.' JNJ-1900 (NBTXR3) is currently the subject of a comprehensive global clinical development program across multiple tumor types and therapeutic combinations, including a pivotal Phase 3 trial in head and neck cancer. About JNJ-1900 (NBTXR3) JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas through a successful randomized Phase 2/3 study in 2018. The product candidate's mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors. Radiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. The program is led by NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study. Given the Company's focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. About NANOBIOTIX Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations. Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. For more information about Nanobiotix, visit us at or follow us on LinkedIn and Twitter Disclaimer This press release contains 'forward-looking' statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company's anticipates its financial resources will be adequate to support operations. Words such as 'expects', 'intends', 'can', 'could', 'may', 'might', 'plan', 'potential', 'should' and 'will' or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company' management's current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix's business and financial performance, which include the risk that assumptions underlying the Company's cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix's Annual Report on Form 20-F filed with the SEC on April 02, 2025 under 'Item 3.D. Risk Factors', in Nanobiotix's 2024 universal registration document filed with the AMF on April 02, 2025,, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC's website at The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly. Contacts Nanobiotix Communications DepartmentBrandon OwensVP, Communications+1 (617) 852-4835contact@ Investor Relations DepartmentJoanne ChoiVP, Investor Relations (US)+1 (713) 609-3150investors@ BhajunDirector, Investor Relations (EU)+33 (0)1 79 97 29 99investors@ Media Relations France – HARDYCaroline Hardy+33 06 70 33 49 Global – uncapped CommunicationsBecky Lauer +1 (646) 286-0057 nanobiotixteam@ Attachment 2025-07-07 -- NTBX -- Composition of Matter Patent for NBTXR3 -- FINALSign in to access your portfolio
Yahoo
an hour ago
- Yahoo
EU Rushes to Conclude a Framework Trade Deal With US This Week
(Bloomberg) -- The European Union is seeking to conclude a preliminary trade deal with the US this week that would allow it to lock in a 10% tariff rate beyond an Aug. 1 deadline as they negotiate a permanent agreement. Are Tourists Ruining Europe? How Locals Are Pushing Back Foreign Buyers Swoop on Cape Town Homes, Pricing Out Locals Trump's Gilded Design Style May Be Gaudy. But Don't Call it 'Rococo.' Denver City Hall Takes a Page From NASA In California, Pro-Housing 'Abundance' Fans Rewrite an Environmental Landmark The EU is seeking an exemption from the 10% rate for certain key products including aircrafts, aircraft parts as well as wine and spirits, according to people familiar with the matter. Some form of relief is expected as part of the agreement in principle. The European Commission, which handles trade matters for the EU, briefed member states Monday on the status of the negotiations. A spokesperson from the commission declined to comment on the ongoing talks. The US announced on Monday that universal tariffs that were due to kick in July 9 would be delayed until at least the beginning of August. For the EU, tariffs on nearly all its exports to the US will jump to 50% on that date if it doesn't strike a deal beforehand. Trump has imposed tariffs on almost all US trading partners, saying he wants to bring back domestic manufacturing, needs to pay for a tax-cut extension and stop other countries from taking advantage of the US. The EU is also pushing the US for quotas and exemptions to effectively lower Washington's 25% tariff on automobiles and car parts as well as its 50% tariff on steel and aluminum, according to the people. But a breakthrough on those levies is not immediately forthcoming. However, the two sides are discussing a so-called offsetting mechanism that would allow companies that make automobiles in the US to export a certain number tariff free, said the people. Some officials are concerned that such an arrangement could see investments and production shift across the Atlantic, Bloomberg previously reported. Any initial deal would likely be short and not legally binding. The two sides are also aiming for common ground on non-tariff barriers, digital trade and economic security. In addition to so-called reciprocal tariffs and sectoral levies on cars and metals, the US is working to introduce duties on other sectors, including pharmaceuticals and semiconductors. Member states are divided on how imbalanced a deal the bloc should accept, with some pushing for a quick agreement while others want the EU to impose countermeasures and negotiate from a position of strength. The EU will assess any end result and at that stage decide what level of asymmetry it's willing to accept and whether any rebalancing measures would be required, Bloomberg previously reported. The EU has approved tariffs on €21 billion ($24.6 billion) of US goods that can be quickly implemented in response to Trump's metals levies. They target politically sensitive US states and include products such as soybeans from Louisiana, home to House Speaker Mike Johnson, as well as agricultural products, poultry and motorcycles. The bloc has also prepared an additional list of tariffs on €95 billion of American products in response to Trump's so-called reciprocal levies and automotive duties. They would target industrial goods including Boeing Co. aircraft, US-made cars, and bourbon. The EU is also consulting member states to identify strategic areas where the US relies on the bloc, as well as potential measures that go beyond tariffs such as export controls and restrictions on procurement contracts. --With assistance from Andra Timu and Milda Seputyte. SNAP Cuts in Big Tax Bill Will Hit a Lot of Trump Voters Too For Brazil's Criminals, Coffee Beans Are the Target 'Telecom Is the New Tequila': Behind the Celebrity Wireless Boom Sperm Freezing Is a New Hot Market for Startups Pistachios Are Everywhere Right Now, Not Just in Dubai Chocolate ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
an hour ago
- New York Times
Newcastle reach agreement with Nottingham Forest for Anthony Elanga signing
Newcastle United have agreed a deal with Nottingham Forest for the signing of Anthony Elanga. A deal consisting of an initial fee of £52million plus bonuses that are considered difficult to reach has been agreed and personal terms are in place on a five-year contract. Elanga is set to undergo a medical in the next 48 hours and he is likely to to link up with his new team-mates by the end of the week. Advertisement The Athletic reported on July 3 that Newcastle were pushing to secure the signing of the winger and a new offer had been made worth more than £50million plus bonuses. The offer came after Forest had rejected a lower bid worth £45million for the 23-year-old in June, having also shown interest in the Sweden international last summer. In 2024, Newcastle were willing to pay a fee worth around £45million ($57m), with the potential package including an initial £30m payment, a swap deal for Paraguay winger Miguel Almiron (valued at £5m, and who has subsequently joined Atlanta United) and two potential further payments of £5m. Elanga joined Forest in July 2023 from Manchester United, who are due a significant sell-on fee, and has appeared 83 times since. The forward played in all 38 of Forest's Premier League games last season. He registered six goals and 11 assists to help the club to a seventh-placed finish that qualified them for the Conference League. Elanga has made 22 appearances for Sweden after his debut in 2022 at the age of 19. The last of which was a 90-minute outing against Hungary in June.
